ICM
HRTX icon

ISZO Capital Management’s Heron Therapeutics HRTX Stock Holding History

ISZO Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-347,051
Closed -$4.83M – 16
2014
Q1 		$4.83M Buy
+347,051
New +$4.64M 2.9% 4

Other funds holding HRTX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SC
Savitr Capital San Francisco, California $57M AUM 14.52% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

ISZO Capital Management's HRTX Position: Q2 2014 in Review

ISZO Capital Management sold out of Heron Therapeutics (HRTX) in Q2 2014, closing a stake of 347,051 shares — an estimated $4.83M sold.

ISZO Capital Management first reported a position in HRTX in Q1 2014 and held it in 1 quarter. The position peaked at $4.83M in Q1 2014. 69 funds tracked by Wall St. Rank hold HRTX as of Q2 2014.

  • ISZO Capital Management reported no remaining Heron Therapeutics position as of Q2 2014 after selling out during the quarter.
  • ISZO Capital Management sold 347,051 Heron Therapeutics shares in Q2 2014, an estimated $4.83M.
  • ISZO Capital Management first reported a position in Heron Therapeutics in Q1 2014 and held it in 1 quarter.
  • ISZO Capital Management's Heron Therapeutics position peaked at $4.83M in Q1 2014.
  • 69 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2014.

Based on ISZO Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.